SCHEMBL3883049

SCHEMBL3883049

O=C(O)CCc1ccc(OC2CCCC2)c(-c2ccc3cn[nH]c3c2)c1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 7/20 0.48
S1PR1 P21453 2/20 0.44
BCL9 O00512 1/20 0.41
CTNNB1 P35222 1/20 0.41
THRA P10827 1/20 0.41
THRB P10828 1/20 0.41
ABL1 P00519 1/20 0.39
CTSC P53634 1/20 0.38
FGFR1 P11362 5/20 0.38
FGFR2 P21802 3/20 0.37
S1PR3 Q99500 1/20 0.37
S1PR5 Q9H228 1/20 0.37
MKNK1 Q9BUB5 1/20 0.37
MKNK2 Q9HBH9 1/20 0.37
LCK P06239 1/20 0.37
BTK Q06187 1/20 0.37
FGFR3 P22607 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3681143 0.92 FFAR4 (0.48) FFAR4S1PR1BCL9CTNNB1THRA
SCHEMBL3884902 0.91 FFAR4 (0.48) FFAR4S1PR1BCL9CTNNB1THRA
SCHEMBL3881066 0.91 FFAR4 (0.48) FFAR4S1PR1BCL9CTNNB1THRA
SCHEMBL3883582 0.90 DDR2 (0.41) FFAR4S1PR1BCL9CTNNB1ABL1
SCHEMBL3883580 0.84 BCL9 (0.40) BCL9CTNNB1ABL1CTSCFGFR1
SCHEMBL3679192 0.83 FFAR4 (0.58) FFAR4S1PR1THRATHRB
SCHEMBL3883590 0.82 FFAR4 (0.53) FFAR4S1PR1THRATHRBLCK
SCHEMBL3679980 0.82 MAPK14 (0.43) FFAR4S1PR1BCL9CTNNB1
SCHEMBL3883711 0.82 FFAR4 (0.57) FFAR4S1PR1THRATHRB
SCHEMBL3884680 0.82 FFAR4 (0.52) FFAR4S1PR1THRATHRBMKNK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1477472-B1 SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF ASAHI KASEI PHARMA CORP (JP) 2009-01-14 EP claimed
CN-100387576-C Substituted phenylalkanoic acid derivatives and use thereof ASAHI CHEMICAL IND (JP) 2008-05-14 CN claimed
CN-1653032-A Substituted phenylalkanoic acid derivatives and use thereof ASAHI CHEMICAL IND (JP) 2005-08-10 CN claimed
US-6867320-B2 Substituted phenylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2005-03-15 US claimed
EP-1477472-A1 SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF Asahi Kasei Pharma Corporation (JP) 2004-11-17 EP claimed
US-20040044258-A1 Substituted phenylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2004-03-04 US claimed
EP-1477472-B1 SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF ASAHI KASEI PHARMA CORP (JP) 2009-01-14 EP disclosed
CN-100387576-C Substituted phenylalkanoic acid derivatives and use thereof ASAHI CHEMICAL IND (JP) 2008-05-14 CN disclosed
CN-1653032-A Substituted phenylalkanoic acid derivatives and use thereof ASAHI CHEMICAL IND (JP) 2005-08-10 CN disclosed
US-6867320-B2 Substituted phenylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2005-03-15 US disclosed
EP-1477472-A1 SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF Asahi Kasei Pharma Corporation (JP) 2004-11-17 EP disclosed
US-20040044258-A1 Substituted phenylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2004-03-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040044258-A1 Substituted phenylalkanoic acid derivatives and use thereof PTGER1, CYSLTR1, PTGS1 FFAR4 115/4885S1PR1 77/4885BCL9 1370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.